Boston Scientific (BSX) beats Q2 2026 EPS estimates for the fifth straight quarter
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Five-quarter earnings beat streak intact as Cardiovascular segment growth of 8.3% powers $0.86 EPS and $5.44 billion revenue, with FARAPULSE pulsed field ablation system delivering clinical momentum and management launching a $500 million cost-reduction push.
Continue ReadingShow less
Boston Scientific reported Q2 2026 earnings per share of $0.86, clearing the Wall Street consensus of $0.83 by roughly 3.9%. Revenue came in at $5.44 billion, about 1.4% above the $5.37 billion estimate. The results extend a five-quarter streak of earnings beats, with the company topping estimates in every period dating back to Q3 2024.
The Cardiovascular segment was the primary engine of the quarter, posting 8.3% growth. Management highlighted the FARAPULSE pulsed field ablation system as a key source of clinical momentum within that segment, suggesting the technology continues to gain procedural traction. Alongside the strong top- and bottom-line numbers, leadership announced a $500 million cost-reduction initiative, signaling an intention to defend and expand margins even as it invests in growth.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Looking at the longer earnings trend, BSX has steadily grown reported EPS from $0.63 in Q3 2024 to $0.86 this quarter, while consistently staying ahead of analyst estimates. The combination of segment-level strength, a high-profile product catalyst in FARAPULSE, and a fresh cost program gives investors several distinct threads to monitor in the quarters ahead.
Mentioned: BSX